关于使用基于结构的计算机辅助方法在胺衍生物的支架上设计抗结核药物的洞察力
Wei Yang1,2,3, Hui Zhao1,2, Ziting Zhao1,2
1National Clinical Research Center for Infectious Diseases, Shenzhen Third People's Hospital Shenzhen 518112 China.
RSC advances
|July 4, 2025
概括
这项研究调查了胺醇氧化支架 (NOS) 衍生品作为潜在的抗结核药物,通过向依赖于迪亚沙夫拉的胺缩酶 (Ddn) 酶. 计算模型确定了设计更有效的抗结核病药物的关键相互作用.
科学领域:
- 药用化学 医学化学
- 计算生物学 计算生物学
- 药物发现 药物发现 药物发现
背景情况:
- 德亚萨弗拉依赖性缩酶 (Ddn) 对于结核病的致病原体Mycobacterium tuberculosis (MTB) 中的酸生物合成至关重要.
- 尼特罗伊米达氧化支架 (NOS) 衍生品被探索为潜在的治疗药物,向DDN以克服耐药性并提高疗效.
研究的目的:
- 阐明NOS衍生品对MTB的结构-活动关系 (SARs) 和绑定机制.
- 为指导新型和强效抗结核剂的合理设计.
主要方法:
- 三维定量结构-活动关系 (3D-QSAR) 研究 (CoMFA和CoMSIA).
- 全原子分子对接和分子动力学 (MD) 模拟.
- 有约束力的自由能量分析和分解.
主要成果:
- 对于最小抑制度 (MIC) 值,CoMFA和CoMSIA模型显示出强大的预测能力 (R cv 2 = 0.5910.629,R pred 2 = 0.68480.7698).
- 分子对接和MD模拟验证了结合模式,并揭示了Ddn活性部位的关键相互作用.
- 已确定Tyr65,Ser78,Tyr130,Tyr133和Tyr136的残留物是抑制剂功效的关键贡献者.
结论:
- 该研究提供了针对Ddn.的NOS衍生品的详细机制理解.
- 已识别的关键残留物和SARs为设计下一代抗结核药物提供了宝贵的见解.
更多相关视频
10:29A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
8.0K
05:08Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
Published on: July 8, 2025
370
相关概念视频
Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Pulmonary Tuberculosis V
243
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
243
Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Targets for Drug Action: Overview
7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K
